Breaking Finance News

Hikma Pharmaceuticals PLC (LON:HIK) stock price target increased to 1,390.00GBX, issued a research note today by Peel Hunt

Yesterday Hikma Pharmaceuticals PLC (LON:HIK) traded 1.69% higher at 954.50GBX. The company’s 50-day moving average is 1,173.53GBX and its 200-day moving average is 1,452.77GBX. The last closing price is down -21.39% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 849,235 shares of the stock traded hands, down from an average trading volume of 888,367

In a report released on 11/14/2017 Peel Hunt increased the stock price target of Hikma Pharmaceuticals PLC (LON:HIK) to 1,390.00GBX indicating a possible upside of 0.46%.

Previously on Friday November 10, 2017, JP Morgan Cazenove reported on Hikma Pharmaceuticals PLC (LON:HIK) reduced the target price from 1,250.00GBX to 1,000.00GBX. At the time, this indicated a possible upside of 0.02%.

See Chart Below

Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals PLC has a 52 week low of 1,101.00GBX and a 52 week high of 2,346.00GBX with a P/E ratio of 16.55 The company’s market cap is currently 0 GBX.

In addition to Peel Hunt reporting its stock price target, a total of 9 brokers have issued a research note on the company. The average stock price target is 32.71GBX with 4 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *